瑞德西韦市场（2026—2031）
瑞德西韦市场规模预计由2026年的82.6亿美元增至2031年的199.1亿美元，预测期复合年增长率为19.23%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
瑞德西韦市场规模预计由2026年的82.6亿美元增至2031年的199.1亿美元，预测期复合年增长率为19.23%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 19.23% | 机构预测 |
| 市场规模 | 2026 | USD 8.26 billion | 机构预测 |
| 市场规模 | 2031 | USD 19.91 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| application | COVID-19 | 2025 | 82.630% |
| distribution_channel | hospital pharmacies | 2025 | 64.630% |
| dosage_form | lyophilized solution | 2025 | 52.380% |
| geography | North America | 2025 | 38.630% |
| patient_age | adults | 2025 | 61.160% |
| route_of_administration | intravenous delivery | 2025 | 71.830% |
关键结论
- application 维度中，COVID-19 在 2025 年的公开份额为 82.63%。
- distribution_channel 维度中，hospital pharmacies 在 2025 年的公开份额为 64.63%。
- dosage_form 维度中，lyophilized solution 在 2025 年的公开份额为 52.38%。
- geography 维度中，North America 在 2025 年的公开份额为 38.63%。
- patient_age 维度中，adults 在 2025 年的公开份额为 61.16%。
- route_of_administration 维度中，intravenous delivery 在 2025 年的公开份额为 71.83%。
主要参与者
- Cipla Limited
- Dr. Reddy’s Laboratories Ltd.
- Hikma Pharmaceuticals PLC
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Broad-Spectrum Antiviral Need | +2.800% | Global | Long term (≥ 4 years) |
| Government Stockpiling and Preparedness Budgets | +2.100% | North America, Europe, MEA | Medium term (2-4 years) |
| Hospital Protocol Expansion for Severe Viral Disease | +1.600% | North America, Europe, Asia-Pacific | Medium term (2-4 years) |
| High-Risk and Immunocompromised Patient Demand | +2.300% | North America, Europe | Long term (≥ 4 years) |
| Access Expansion in Emerging Healthcare Markets | +1.800% | Asia-Pacific, MEA, South America | Long term (≥ 4 years) |
| Post-Acute and Long-Duration Viral Care Pathways | +1.200% | North America, Europe | Medium term (2-4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Falling COVID-19 Hospitalization Burden | -1.900% | North America and Europe | Short term (≤ 2 years) |
| Viral Resistance and Therapeutic Substitution | -1.400% | Global | Medium term (2-4 years) |
| Sterile Injectable Manufacturing and Distribution Costs | -1.100% | Global | Long term (≥ 4 years) |
| Hospital Formulary Deprioritization | -0.900% | North America, Europe, Oceania | Short term (≤ 2 years) |
报告关注的关键问题
What is the projected size of the remdesivir market by 2031?
The remdesivir market is forecast to reach USD 19.91 billion by 2031, from USD 8.26 billion in 2026, at a 19.23% CAGR. Hospital demand, preparedness purchasing, and generic access support this outlook.
Which route of administration leads remdesivir sales?
Intravenous delivery led with 71.83% share in 2025 because treatment remains closely tied to hospital-based infusion care. Hospital protocols and supervised dosing continue to support this route.
Why is MERS-CoV the fastest-growing remdesivir application?
MERS-CoV is forecast to grow at a 20.94% CAGR through 2031 as Gulf health systems maintain preparedness procurement for endemic respiratory risk. The application remains smaller than COVID-19 but adds a distinct regional demand source.
What is driving pediatric remdesivir demand?
The pediatric segment is forecast to grow at a 19.57% CAGR through 2031, supported by the EMA recommendation for children from 4 weeks of age and at least 3 kg. The label change broadens eligibility in hospital procurement.
Which region is growing fastest for remdesivir?
Asia-Pacific is forecast to grow at a 19.64% CAGR through 2031, supported by Indian generic supply, Chinese hospital demand, and Japanese treatment protocols. India also serves as an export manufacturing base.
What is the main challenge for remdesivir suppliers?
Falling COVID-19 hospitalizations constrain demand, while sterile injectable manufacturing costs and potential oral substitution affect supplier economics. These pressures are strongest where outpatient care replaces hospital treatment.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence